In a study of drivers with past year alcohol and cannabis use, researchers at Columbia University Mailman School of Public Health found that two in five drivers reporting alcohol and cannabis in the past year drove under the influence of alcohol, cannabis or both. Approximately one-half of the participants in each category reported this pattern. The findings are published in the American Journal of Preventive Medicine.
Earlier research has suggested that simultaneous alcohol and cannabis use increases driving impairment, leading to an uptick in the risk of traffic fatality more than either substance individually, particularly among young adolescents. Yet, until now, no nationally representative study has tested relationships simultaneous use and people reporting driving under the influence of these substances.
“Alcohol and cannabis are two of the most common substances involved in impaired driving and motor vehicle crashes in the U.S.,” said Priscila Dib Gonçalves in the Department of Epidemiology at Columbia Mailman School, and first author. “Examining the effect of simultaneous alcohol and cannabis use on self-report driving under the influence (DUI) of alcohol-only, cannabis-only, and both substances using a nationally representative sample could contribute to better understanding the impact in adolescents and adults.”
Drivers aged 16 years or older who reported any past-year alcohol and cannabis use in the National Survey on Drug Use and Health (2016-2019) were included with a final study sample of 34,514. The outcome was reporting any past-year driving under the influence of alcohol-only (DUI-A), cannabis-only (DUI-C), alcohol and cannabis (DUI-A+C), or no DUI. Data were further collected via face-to-face household interviews using computer-assisted interviewing and audio computer-assisted survey instruments to increase the accuracy of responses to potentially sensitive questions.
Between 2016-2019, 42 percent of drivers with past-year alcohol and cannabis use reported any past-year DUI (8 percent DUI-A, 20 percent DUI-C, 14 percent DUI-A+C). Simultaneous use was associated with 2.88 times higher odds of driving under the influence of cannabis, and 3.51 times higher odds of driving under the influence of both alcohol and cannabis.
Most participants were male (57 percent), non-Hispanic white (67 percent) with a family income of $40,000 or less (63 percent), and living in a state with medical cannabis laws (68 percent). Two-thirds of participants reported any tobacco use in the past year and one-third used any drug other than cannabis. In addition, 8 percent reported daily alcohol use, 20 percent daily cannabis use, and 21 percent met criteria for alcohol use disorder and 18 percent for cannabis use disorder. Over a quarter of the sample (28 percent) reported simultaneous alcohol/cannabis use.
Daily alcohol and cannabis use increased the likelihood of DUI-A and DUI-C, respectively, and both alcohol/cannabis daily use were associated with DUI-A/C. “In the context of increasing daily cannabis use among adults, our findings connecting daily cannabis use and DUI raises public health concerns,” observed Pia Mauro, PhD, assistant professor of epidemiology, and senior author. “Population changes in cannabis use frequency that may be associated with health hazards, including daily use, need to be continuously monitored.”
“Our study is unique in that it reports more recent nationally representative data (2016-2019) and compares different types of DUI categories,” noted Gonçalves. “From a harm reduction perspective, identifying which population subgroups are at high risk for DUIs could assist the development of more focused prevention strategies. Future research should also investigate the potential impact of low or “promotional” cannabis prices with higher levels of use, intoxication, and simultaneous use of other substances.”
Co-authors are Sarah Gutkind, Luis Segura, João M. Castaldelli-Maia, and Silvia Martins, Columbia University Mailman School of Public Health.
The study was funded by the US National Institutes of Health, National institute on Drug Abuse, T32DA031099, R01DA037866 and K01 DA045224, and the National Center for Injury Prevention and Control, R49CE003094.
Columbia University Mailman School of Public Health
Founded in 1922, the Columbia University Mailman School of Public Health pursues an agenda of research, education, and service to address the critical and complex public health issues affecting New Yorkers, the nation and the world. The Columbia Mailman School is the fourth largest recipient of NIH grants among schools of public health. Its nearly 300 multi-disciplinary faculty members work in more than 100 countries around the world, addressing such issues as preventing infectious and chronic diseases, environmental health, maternal and child health, health policy, climate change and health, and public health preparedness. It is a leader in public health education with more than 1,300 graduate students from 55 nations pursuing a variety of master’s and doctoral degree programs. The Columbia Mailman School is also home to numerous world-renowned research centers, including ICAP and the Center for Infection and Immunity. For more information, please visit www.mailman.columbia.edu.
American Journal of Preventive Medicine